New ALS drug trial hopes to slow disease progression
Disease control
ENROLLING_BY_INVITATION
This clinical trial is testing an oral drug called NUZ-001 in 160 people with ALS. Participants take the drug or a placebo daily for 36 weeks. The study measures how the disease progresses using a scale of physical function and survival. The goal is to see if NUZ-001 can slow ALS…
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC